News
Unigene to Present at the 20th Annual Roth Capital Partners Growth Stock Conference
Unigene Laboratories, Inc.’s President and CEO, Dr. Warren Levy, will speak at the ROTH Capital Partners Growth Stock Conference on Thursday, February 21, 2008. Dr. Levy will present information on Unigene’s products and collaborations to analysts, portfolio managers, investment bankers and other financial professionals. The conference will be held at The Ritz Carlton, Laguna Niguel, CA, February 18-21, 2008.
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical® to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.